3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Irinotecan
5
Docetaxel
4
Cisplatin
4
Carboplatin
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
pazopanib
2
palbociclib
2
liposomal doxorubicin
2
entrectinib
2
alectinib
2
Vinorelbine
2
Trastuzumab
2
Taxes
2
Radiosurgery
2
Oncolytic Virotherapy
2
Observation
2
Ipilimumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled